Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of Dana-Farber Cancer Institute. In vivo CAR T-cell therapy could drastically ...
A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...
Gilead Sciences broke into the field of cancer cell therapies through an acquisition. Now it’s aiming to be part of the next generation of such therapies by buying clinical-stage Interius ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results